2024 GRI Index
Fresenius Medical Care has reported the information cited in this Global Reporting Initiative (GRI) content index for the period from 1 January 2024 to 31 December 2024 with reference to the GRI Standards. This disclosure is part of our commitment to provide transparent and relevant information on our economic, environmental, and social performance to our stakeholders.
GRI 1 used: GRI 1: Foundation 2021
| GRI Standard | Link | Comment | |
|---|---|---|---|
| The organization and its reporting practices | |||
| 2‑1 | Organizational details | ||
| 2-2 | Entities included in the organization’s sustainability reporting | Sustainability Statement: General information Notes to Consolidated Financial Statements: Principal subsidiaries |
|
| 2-3 | Reporting period, frequency and contact point | Contact | The reporting period is from January 1 to December 31, 2024. In compliance with German Commercial Law, we apply a yearly reporting cycle. Our most recent Annual Report, including our Sustainability Statement 2024, was published on March 13, 2025. |
| 2-4 | Restatements of information | Information on Metrics and Targets | |
| 2-5 | External assurance | Report by the Supervisory Board: Separate Non-Financial Group Report |
|
| Activities and workers | |||
| 2-6 | Activities, value chain and other business relationships | Overview of the Group: Business model |
|
| 2-7 | Employees | ||
| 2-8 | Workers who are not employees | We are implementing processes to include non-employees in our reporting. | |
| Governance | |||
| 2-9 | Governance structure and composition | Report by the Supervisory Board: Committees of the Supervisory Board |
|
| 2-10 | Nomination and selection of the highest governance body | Declaration on Corporate Governance Declaration on Corporate Governance: Supervisory Board of the Company Declaration on Corporate Governance: Diversity concept and targets |
|
| 2-11 | Chair of the highest governance body | Declaration on Corporate Governance | |
| 2-12 | Role of the highest governance body in overseeing the management of impacts | ||
| 2-13 | Delegation of responsibility for managing impacts | Responsibility for the management of sustainability topics and impacts is described in the respective chapters of the Sustainability Statement. | |
| 2-14 | Role of the highest governance body in sustainability reporting | Sustainability management: Sustainability Governance | The Sustainability Statement is reviewed and approved by our Chief Executive Officer, Helen Giza. |
| 2-15 | Conflicts of interest | Report by the Supervisory Board: Corporate Governance |
We have a policy on conflicts of interest, reflecting our commitment to minimize them. A conflict of interest is any situation/engagement (activity/relationship) that may (potentially) create a conflict to the legitimate interests of FME; or can be perceived as creating a conflict to the legitimate interest of FME. It may arise when personal interests of an employee (resulting from engagements, activities, situations, relationships, etc.) are in conflict with legitimate interests of FME. Conflicting interests may impact the employee’s objectivity and their ability to perform their employment duties in the best interests of FME. A COI as per this Policy includes actual, potential or perceived Conflicts of Interest. Potential conflicts of interest are disclosed via a disclosure form, which is part of the policy/standard operating procedure and reflected in training and guidance materials. |
| 2-16 | Communication of critical concerns | Compliance and Business Ethics | |
| 2-17 | Collective knowledge of the highest governance body | Sustainability management: Sustainability Governance Supervisory Board website: Lead Independent Director and ESG expertise |
|
| 2-18 | Evaluation of the performance of the highest governance body | ||
| 2-19 | Remuneration policies | ||
| 2-20 | Process to determine remuneration | Compensation Report | |
| 2-21 | Annual total compensation ratio | Compensation Report: Comparative presentation of the development of the compensation |
|
| Strategy, policies and practices | |||
| 2-22 | Statement on sustainable development strategy | Sustainability Management: Strategy | |
| 2-23 | Policy commitments | ||
| 2-24 | Embedding policy commitments | Sustainability management: Strategy Code of Ethics and Business Conduct Global Code of Conduct for Business Partners |
Approaches to embed policy commitments throughout activities and business relationships are described in the respective chapters of the Sustainability Statement. |
| 2-25 | Processes to remediate negative impacts | ||
| 2-26 | Mechanisms for seeking advice and raising concerns | Code of Ethics and Business Conduct |
|
| 2-27 | Compliance with laws and regulations | Legal matters that Fresenius Medical Care deems to be material or noteworthy are described in the annex of our Annual Report and our 20-F. | |
| 2-28 | Membership associations | Sustainability Management: Interests and View of Stakeholders Human Rights: Engaging with Stakeholders on Impacts - SuS |
|
| Stakeholder engagement | |||
| 2-29 | Approach to stakeholder engagement | Sustainability Management: Interests and View of Stakeholders | Approach to stakeholder engagement is also adressed in all chapters of the Sustainability Statement. |
| 2‑30 | Collective bargaining agreements | Working for Fresenius Medcial Care: Dialogue with Employees and their Representatives |
|
| GRI Standard | Link | Comment | |
|---|---|---|---|
| GRI 3: Material Topics 2021 | |||
| 3-1 | Process to determine material topics | Sustainability Management: Double Materiality Assessment | |
| 3-2 | List of material topics | Sustainability Management: Double Materiality Assessment | |
| 3‑3 | Management of material topics | Sustainability Management: Double Materiality Assessment | |
| GRI Standard | Link | Comment | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GRI 201: Economic Performance 2016 | |||||||||||||||||||||||||||
| 201-1 | Direct economic value generated and distributed | Overview of the Group: Performance management system Economic report: Results of operations, financial position and net assets Notes to Consolidated Financial Statements: Personnel expenses |
|||||||||||||||||||||||||
| 201-2 | Financial implications and other risks and opportunities due to climate change | Risks and Opportunities Report: ESG requirements Sustainability Management: Risk and Opportunity Management Notes to Consolidated Financial Statements: Impacts of climate change on accounting |
|||||||||||||||||||||||||
| 201-3 | Defined benefit plan obligations and other retirement plans | Notes to Consolidated Financial Statements: Employee benefit plans | |||||||||||||||||||||||||
| 201-4 | Financial assistance received from government | Economic Report | |||||||||||||||||||||||||
| GRI 204: Procurement Practices 2016 | |||||||||||||||||||||||||||
| 204-1 | Proportion of spending on local suppliers | The amount spent on local suppliers represents 84% of the total amount spent. Local refers to supplier that operates within the same country as our local business unit conducting the procurement. | |||||||||||||||||||||||||
| GRI 205: Anti-corruption 2016 | |||||||||||||||||||||||||||
| 205-1 | Operations assessed for risks related to corruption |
|
|||||||||||||||||||||||||
| 205-2 | Communication and training about anti-corruption policies and procedures | Compliance and Business Ethics | |||||||||||||||||||||||||
| 205-3 | Confirmed incidents of corruption and actions taken | ||||||||||||||||||||||||||
| GRI 207: Tax 2019 | |||||||||||||||||||||||||||
| 207-1 | Approach to tax | Group Tax Policy | As a global provider of products and services for people with kidney diseases, we are active in more than 100 countries. Due to our business activities, we are subject to various local tax obligations. In the countries in which we operate, we not only support the development of health care systems, but also create jobs that contribute to local tax revenue. This enables us to make a significant contribution to preserving the macroeconomic stability of national economies. The basis for paying taxes is the business activities of Fresenius Medical Care in a country. When choosing a location, many other aspects such as the availability of qualified personnel, or political, economic, legal, and regulatory framework conditions play a role in addition to strategic business issues. In the course of an overall assessment, the possibility of minimizing currency risks as well as tax considerations can also influence the choice of location. The global distribution of business activities results in transactions between the individual companies of the Fresenius Medical Care Group worldwide. The pricing of these intercompany transactions is based on the internationally recognized arm's length principle and is in line with the OECD transfer pricing guidelines and the respective local transfer pricing rules. This ensures that profits are generated and taxed where value is created. The intercompany transactions are documented on the basis of legal requirements in accordance with the applicable OECD guidelines and are disclosed to tax authorities upon request. |
||||||||||||||||||||||||
| 207-2 | Tax governance, control, and risk management | Group Tax Policy | Fresenius Medical Care is committed to complying with all relevant tax laws and regulations in the countries where it operates. We seek to identify, assess, and mitigate tax risks through appropriate internal controls and processes, and we consult external tax experts when necessary to ensure tax risks are properly managed. We regularly monitor compliance with our tax policies and procedures through internal audits and controls. These reviews aim to ensure that we meet our tax obligations and that potential risks are identified and addressed early. Furthermore we have implemented a global risk management system that also covers tax risks. In 2022, we mandated an independent external tax auditor to review our Tax Compliance Management System (Tax CMS) in Germany based on an auditing standard (IDW PS 980) and OECD standards. The audit report confirmed that we appropriately mitigate tax-related risks. After Fresenius Medical Care’s change in legal form as well as after the deconsolidation and with ongoing publication of new tax legislation the Tax CMS has been adjusted to the updated tax related processes and tax risks. |
||||||||||||||||||||||||
| 207-3 | Stakeholder engagement and management of concerns related to tax | Fresenius Medical Care has outlined its approach to stakeholder engagement and management of concerns related to tax in its Group Tax Policy. We emphasize maintaining a culture where all employees recognize the importance of adhering to tax laws and handling tax matters correctly. This commitment reflects the company's core values, including integrity and responsibility. Fresenius Medical Care does not specifically settle in certain countries in order merely to generate tax benefits or create tax structures – the focus is always on our business activities. Information on ways to report suspected acts of non-compliance can be found in our Sustainability Statement. |
|||||||||||||||||||||||||
| 207‑4 | Country-by-country reporting |
|
|||||||||||||||||||||||||
| Additional Material Topic: Innovation and R&D | |||||||||||||||||||||||||||
| 3-3 | Management of material topics | ||||||||||||||||||||||||||
| GRI Standard | Link | Comment | |
|---|---|---|---|
| GRI 302: Energy 2016 | |||
| 302-1 | Energy consumption within the organization | Climate Change | a) consumption from non-renewable sources: 5,859,280 GJ b) consumption from renewable sources: 0 GJ c) energy consumption: i) electricity: 1.282.949 MWH ii) heating: 26,115 MWH iii) cooling: 0 MWH iv) steam: 0 MWH d) energy sold: i) electricity: 8,958,375 MWH ii) heating: 0 MWH iii) cooling: 0 MWH iv) steam: 0 MWH e) total consumption: 10,666,711 GJ f) see metrics section in chapter "Climate Change" in the Sustainability Statement for standards used g) Source of the conversion factors used: DEFRA |
| 302-3 | Energy intensity | a) Energy intensity ratio: 0,00004 b) Organization-specific metric (the denominator) chosen to calculate the ratio: 19335908807 EUR c) Types of energy included in the intensity ratio: all d) Whether the ratio uses energy consumption within the organization, outside of it, or both: within the organization |
|
| GRI 303: Water and Effluents 2018 | |||
| 303-1 | Interactions with water as a shared resource | Water | |
| 303-2 | Management of water discharge related impact | Water | |
| 303-3 | Water withdrawal | Water | a) Water withdrawal: 35.2 Million m3, 35,200 Million liters Municipal water: 34.9 Million m3, 34,900 Million liters Ground water: 0.3 Million m3, 300 Million liters
b) Water withdrawal from all areas with water stress : 7.4 Million m3, 7,400 Million liters |
| 303-4 | Water discharge | Water | a) Water discharge 32.4 Million m3, 32,400 Million liters |
| GRI 305: Emissions 2016 | |||
| 305-1 | Direct (Scope 1) GHG emissions | Climate Change | a) Gross direct (Scope 1) GHG emissions in metric tons of CO2 equivalent: 360802 b) Gases included in the calculation: all c) Biogenic CO2 emissions in metric tons of CO2 equivalent: 0 d) Base year for the calculation: 2020 i) the rationale for choosing it: The energy and emission data of 2020 met the requirements of relevance, completeness, consistency, transparency, and accuracy. ii) emissions in the base year: 376906 iii) the context for any significant changes in emissions that triggered recalculations of base year emissions: scope extension to include all Scope 1 and 2 emission sources in 2024 for a complete reporting. e) Source of the emission factors and the global warming potential (GWP) rates used: Department for Environment, Food & Rural Affairs; GWPs are included in the emissions factors from the sources above or taken from IPCC AR6 f) see metrics section in chapter "Climate Change" in the Sustainability Statement for consolidation approach for emissions g) see metrics section in chapter "Climate Change" in the Sustainability Statement for Standards, methodologies, assumptions, and/or calculation tools used |
| 305-2 | Energy indirect (Scope 2) GHG emissions | Climate Change | a) Gross location-based energy indirect (Scope 2) GHG emissions in metric tons of CO2 equivalent: 450611 b) Gross market-based energy indirect (Scope 2) GHG emissions in metric tons of CO2 equivalent: 326635 c) Gases included in the calculation: all d) Base year for the calculation: 2020 i) the rationale for choosing it: The energy and emission data of 2020 met the requirements of relevance, completeness, consistency, transparency, and accuracy. ii) emissions in the base year: 538824 market-based iii) the context for any significant changes in emissions that triggered recalculations of base year emissions: scope extension to include all Scope 1 and 2 emission sources in 2024 for a complete reporting. e) Source of the emission factors and the global warming potential (GWP) rates used: Scope 2 location-based emission factors are utilized from the International Energy Agency (IEA). Scope 2 market-based emission factors are utilized from US Residual Mix (Green-e Energy Emissions Rates), RE-DISS Residual European Mix, and the International Energy Agency (IEA). Location and market based emission factors are extracted from our energy reporting tool, Resource Advisor. GWPs are included in the emissions factors from the sources above or taken from IPCC AR6 f) see metrics section in chapter "Climate Change" in the Sustainability Statement for consolidation approach for emissions g) see metrics section in chapter "Climate Change" in the Sustainability Statement for Standards, methodologies, assumptions, and/or calculation tools used |
| 305-3 | Other indirect (Scope 3) GHG emissions |
Climate Change | a) Gross other indirect (Scope 3) GHG emissions in metric tons of CO2 equivalent: 2881287 b) Gases included in the calculation: all c) Biogenic CO2 emissions in metric tons of CO2equivalent: N/A d) Other indirect (Scope 3) GHG emissions categories and activities included in the calculation: No e) Base year for the calculation: 2024 i) the rationale for choosing it: first year of full Scope 3 reporting ii) emissions in the base year: 2881287 iii) the context for any significant changes in emissions that triggered recalculations of base year emissions.: N/A f) Source of the emission factors and the global warming potential (GWP) rates used: DEFRA, IEA, estell 6 g) Standards, methodologies, assumptions, and/or calculation tools used: All calculations follow recommendations and guidance from GHG Protocol |
| 305-4 | GHG emissions intensity | Climate Change | a) GHG emissions intensity ratio: 0,0000356 b) Organization-specific metric (the denominator) chosen to calculate the ratio: 19335908807 (Total revenue in EUR) c) Types of GHG emissions included in the intensity ratio: Scope 1 and market based scope 2 d) Gases included in the calculation: all |
| 305-5 | Reduction of GHG emissions | Climate Change | |
| GRI 306: Waste 2020 | |||
| 306-1 | Waste generation and significant waste-related impacts | Resource Use and Circular Economy | We evaluate our effects on people and the environment through impact and local community assessments. This includes reviewing how our waste generation affects ecosystems. These assessments were based on internal and external data, such as waste data, proximity to residential areas, external risk factors, and national waste management indices. Our Care Delivery and Care Enablement segments generate different types of waste. Waste from patient treatments in our centers is primarily composed of disposable dialysis and medical products, including dialyzers and bloodlines. These disposables are not suitable for recycling, as they may come into contact with blood. The packaging of these products, which meet strict hygiene requirements, consists of multiple materials, making recycling more challenging. Waste from manufacturing sites, dialysis clinics, and other facilities constitutes a significant proportion of our total waste. This includes chemical waste, solvents, plastics, and general waste. |
| 306-2 | Management of significant waste-related impacts | Resource Use and Circular Economy | a) Developing a circular economy strategy In 2024, we developed a global circular economy strategy through a structured process involving multiple internal stakeholders, including relevant business units, sustainability experts, and senior leadership. The Management Board approved the strategic principles. Our strategy is designed to optimize resource efficiency, reduce our carbon footprint, and comply with evolving regulatory requirements. It reflects our commitment to integrating circular economy principles into our operations and value chain. We plan to begin implementing our circular economy action plan in 2025, with initial actions expected over the next two to three years. Waste management and reporting Waste is currently managed at a regional or local level due to varying local regulations and the nature of waste disposal. We aim to establish global processes and guidelines to improve waste segregation at the source, enabling better identification of materials for recycling or reuse. Implementation will partly depend on regulatory opportunities to influence local waste management infrastructure. b) To manage the impacts, risks, and opportunities in our value chain related to waste management, our Supplier Code of Conduct defines the standards we require from suppliers. They are expected to set environmental targets, define strategies, and implement policies to identify and mitigate environmental impacts in their operations and supply chains. The Supplier Code of Conduct covers potential impacts and risks related to resource use, waste management, and handling of hazardous substances. Environmental criteria are also included in the selection process for new suppliers. c) Waste reporting: In the reporting year, we expanded the scope of our resource use reporting to improve transparency. We established processes for reporting material inflows required to manufacture products and provide dialysis in our clinics. Global waste reporting processes for our business segments were also introduced, covering total waste, hazardous and non-hazardous waste, and waste treatment methods. |
| 306-3 | Waste Generated | Resource Use and Circular Economy | a) Total Waste: 199,407 metric tons Hazardous Waste: 47,800 metric tons Non-Hazardous Waste: 151,607 metric tons b) Data for the Care Enablement segment are manually collected and categorized by waste type and treatment method. They may include estimations. For the Care Delivery segment, data come from supplier reports and internal systems. Where primary data is unavailable, extrapolations or estimations are based on waste generation factors from similar activities. An internal study of in-center dialysis clinic waste assumes that the amount of non-hazardous waste equals the amount of blood-contaminated waste. |
| 306-4 | Waste diverted from disposal | Resource Use and Circular Economy | a) Hazardous waste diverted from disposal: 552 mt Non-Hazardous waste diverted from disposal: 71,018 mt b) Hazardous waste
c) Non-hazardous waste
d) N/A e) Data for the Care Enablement segment are manually collected and categorized by waste type and treatment method. They may include estimations. For the Care Delivery segment, data come from supplier reports and internal systems. Where primary data are unavailable, extrapolations or estimations are based on waste generation factors from similar activities. If primary data on the treatment method are unavailable, hazardous and non-hazardous waste amounts are estimated using general assumptions or reference values from statistical databanks in respective countries. |
| 306-5 | Waste diverted from disposal | Resource Use and Circular Economy | a) Hazardous waste directed to disposal: 47,248 mt Non-Hazardous waste directed to disposal: 80,589 mt b) Hazardous waste
c) Non-hazardous waste
d) N/A e) Data for the Care Enablement segment are manually collected and categorized by waste type and treatment method. They may include estimations. For the Care Delivery segment, data come from supplier reports and internal systems. Where primary data are unavailable, extrapolations or estimations are based on waste generation factors from similar activities. If primary data on the treatment method are unavailable, hazardous and non-hazardous waste amounts are estimated using general assumptions or reference values from statistical databanks in respective countries. |
| GRI 308: Supplier Environmental Assessment 2016 | |||
| 308-1 | New suppliers that were screened using environmental criteria | Sustainability in the Value Chain | |
| 308‑2 | Negative environmental impacts in the supply chain and actions taken | ||
| GRI Standard | Link | Comment | |
|---|---|---|---|
| GRI 401: Employment 2016 | |||
| 401-1 | New employee hires and employee turnover | Working for Fresenius Medical Care | |
| 401-2 | Benefits provided to full-time employees that are not provided to temporary or part-time employees | Working for Fresenius Medical Care |
|
| 401-3 | Parental leaves | We offer statutory paid parental leave in various countries. We will continue to evaluate our leave offerings. | |
| GRI 403: Occupational Health and Safety 2018 | |||
| 403-1 | Occupational health and safety management system | We have implemented a company-wide Occupational Health and Safety (OHS) management system. It considers applicable legal requirements, including EU Directives, regulations from the U.S. Occupational Health and Safety Administration (OSHA), and other national labor laws. We plan to expand the system's coverage to include non-employees starting in 2025 reporting. |
|
| 403-2 | Hazard identification, risk assessment, and incident investigation | We identify hazards at the dialysis clinics and production sites that we control directly. Identified hazards are evaluated based on their severity and/or frequency to determine their likelihood of causing harm. Once this step has been taken, appropriate measures to reduce the hazards and any related risks are identified and adopted. As an example of actions taken, regular meetings are carried out at production sites in Europe, Middle East and Africa to share best practices, discuss lessons learned from accidents, and identify significant near misses. We are assessing the possibility to digitalize these processes in the coming years to ensure a global alignment.
All actions to mitigate hazards are assigned to a specific EHS department in the North America region and to local HR or OHS representatives in the other regions. Incident investigation is a locally managed process that covers all employees. Thanks to the newly introduced system some locations have the possibility to use a voluntary available investigation tool.
Our policy states that employees and contractors receive information, instructions, and training on occupational health and safety as required. They are encouraged to report, discuss, and learn from safety-related events and concerns in a transparent and open manner. Employees and contractors can remove themselves from work situations they believe could cause injury or ill health, and our policy fosters a culture where such concerns can be raised without fear of reprisal. |
|
| 403-3 | Occupational health services | Global Occupational Health and Safety Policy | Fresenius Medical Care provides several occupational health services based on the legal requirements of the locations in which we operate. Both in dialysis clinics and production sites, these services are managed and overlooked by specifically trained employees at regional, national, and local levels. |
| 403-4 | Worker participation, consultation, and communication on occupational health and safety | As highlighted in our Global Occupational Health and Safety Policy, we strive to facilitate consultations on OHS matters with employees and contractors, where appropriate. Therefore, we plan and implement consultation sessions with employees and management on OHS-related topics to establish concerns and improvement areas. As we work towards centralization of governance, we aim to create a structure that simplifies the connection between employees and management levels to allow easier consultation processes at all levels. Regular consultations take place yearly at regional level. In 2024 the OHS global function has joined some of these meetings aiming at hearing feedback and needs directly from country representatives Our OHS expert group met every month and their responsibility is to develop globally aligned actions plans that define and prioritize key measures for the organization. |
|
| 403-5 | Worker training on occupational health and safety | Working for Fresenius Medical Care | Training on occupational health and safety follows national legislation requirements. All employees who are required to undertake training are closely monitored, and completion rates are checked. A long-term goal is to structure a global training framework in the years to come. |
| 403-6 | Promotion of worker health | Depending on the location, we offer a wide range of benefits aimed at promoting employee health. These benefits focus on preventing illness and injury. Offers include fitness and sport activities, as well as nutrition and safety courses. An example is the initiative Health at Work at Fresenius Medical Care’s headquarters, which includes a variety of classes, workshops, and events to help employees stay fit and healthy. In North America, the HR department set up a platform aimed at supporting employees during difficult moments. The goal is to offer this initiative globally. | |
| 403-7 | Prevention and mitigation of occupational health and safety impacts directly linked by business relationships | ||
| 403-8 | Workers covered by an occupational health and safety management system | We consider the percentage of employees covered by an occupational health and safety management system to be 100%. At this stage, workers who are not employees but whose work and/or workplace is controlled by the organization are not covered under the OHS management system. However, we plan to expand the system's coverage to include non-employees starting in 2025 reporting. | |
| 403-9 | Work-related injuries | We are committed to providing a safe and healthy work environment and strive to prevent work-related accidents and hazards to protect our employees and contractors. In recent years, we have established a centralized reporting process for work-related fatalities, Total Recordable Injury Frequency Rate (TRIFR), and Lost Time Injury Frequency Rate (LTIFR). These metrics are published in the Sustainability Statement. Non-employee workers were not included in data of 2024, but processes are being developed for inclusion in 2025. In our clinics and plants, the most frequently reported injuries typically result in no more than one day lost, mainly due to needlestick and sharps-related injuries. |
|
| 403‑10 | Work-related ill health | We currently do not report the number and rates of work-related ill health. For North America, these figures are included as part of the OSHA rates. At present, responsibility for OHS lies at the regional level. Starting in 2025, we expect to begin reporting work-related ill health figures for employees. | |
| GRI 404: Training and Education 2016 | |||
| 404-1 | Average hours of training per year per employee | ||
| 404-2 | Programs for upgrading employee skills and transition assistance programs | Working for Fresenius Medical Care | |
| 404-3 | Percentage of employees receiving regular performance and career development reviews | Working for Fresenius Medical Care |
|
| GRI 405: Diversity and Equal Opportunity 2016 | |||
| 405-1 | Diversity of governance bodies and employees | Working for Fresenius Medical Care: Metrics Declaration on Corporate Governance: Diversity concept and targets |
|
| 405-2 | Ratio of basic salary and remuneration of women to men | We report on remuneration ratio of women to men for total compensation, but not for basic salary. | |
| GRI 406: Non-discrimination 2016 | |||
| 406-1 | Incidents of discrimination and corrective actions taken | Code of Ethics and Business Conduct |
|
| GRI 407: Freedom of Association and Collective Bargaining 2016 | |||
| 407-1 | Operations and suppliers in which the right to freedom of association and collective bargaining may be at risk | Sustainability in the Value Chain Working for Fresenius Medical Care: Engaging our Employees on Impacts Global Code of Conduct for Business Partners |
|
| GRI 408: Child Labor 2016 | |||
| 408-1 | Operations and suppliers at significant risk for incidents of child labor | Our commitment to preventing child labor from occurring within both our business and supply chain is defined in several company policies, such as our Code of Ethics and Business Conduct, our Human Rights Statement, Supplier Code of Conduct and our Compliance Brochure for our Business Partners. It is further specified in our policies and procedures. Moreover, our Global Code of Conduct for Business Partners requires that suppliers shall condemn exploitative child labor and shall not employ workers under the minimum age for regular employment as defined by applicable national legislation or international conventions. |
|
| GRI 409: Forced or Compulsory Labor 2016 | |||
| 409-1 | Operations and suppliers at significant risk for incidents of forced or compulsory labor | Our commitment to preventing forced or compulsory labor from occurring within both our business and supply chain is defined in several company policies, such as our Code of Ethics and Business Conduct, our Human Rights Statement, Supplier Code of Conduct and our Compliance Brochure for our Business Partners. It is further specified in our policies and procedures. We do not tolerate the use or threat of violence, or any other form of coercion. We strictly forbid using, supporting, or approving any form of exploitative labor, child labor or forced labor. Employment relationships must be based on voluntary participation. Hence, our employees can choose to terminate their employment of their own free will by respecting a reasonable pre-notification period, as applicable. Our Global Code of Conduct for Business Partners stipulates that suppliers shall take a clear stance against forced labor and any form of exploitative child labor and shall not engage in any form of non-voluntary, forced or compulsory labor. |
|
| GRI 414: Supplier Social Assessment 2016 | |||
| 414-1 | New suppliers that were screened using social criteria | Sustainability in the Value Chain Compliance and Business Ethics
|
|
| 414-2 | Negative social impacts in the supply chain and actions taken | Sustainability in the Value Chain | |
| GRI 415: Public Policy 2016 | |||
| 415-1 | Political contributions | ||
| GRI 416: Customer Health and Safety 2016 | |||
| 416-1 | Assessment of the health and safety impacts of product and service categories | Product Stewardship | For all our medical devices, in-vitro diagnostics, and pharmaceuticals, we assess and manage the risks to and impact on the health and safety of our patients. For these products, we assess 100% of our significant product categories. This risk and impact assessment is performed according to international standards such as ISO 14971 and ICH Q9. |
| 416-2 | Incidents of non-compliance concerning the health and safety impacts of products and services | Risks and Opportunities Report Notes to Consolidated Financial Statements: Commitments and contingencies |
Legal matters that Fresenius Medical Care currently deems to be material or noteworthy are described in the annex of our Annual Report and our 20-F. |
| GRI 417: Marketing and Labeling 2016 | |||
| 417-1 | Requirements for product and service information and labeling | Code of Ethics and Business Conduct | |
| 417-2 | Incidents of non-compliance concerning product and service information and labeling | Legal matters that Fresenius Medical Care currently deems to be material or noteworthy are described in the annex of our Annual Report and our 20-F. | |
| 417‑3 | Incidents of non-compliance concerning marketing communications | 'Legal matters that Fresenius Medical Care currently deems to be material or noteworthy are described in the annex of our Annual Report and our 20-F. | |
| GRI 418: Customer Privacy 2016 | |||
| 418-1 | Substantiated complaints concerning breaches of customer privacy and losses of customer data | ||